Published in Mol Cell Biol on March 31, 2014
Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci (2014) 1.01
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front Mol Neurosci (2014) 1.01
LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener (2016) 0.83
A visual review of the interactome of LRRK2: Using deep-curated molecular interaction data to represent biology. Proteomics (2015) 0.82
The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem J (2016) 0.79
LRRK2 Regulates Voltage-Gated Calcium Channel Function. Front Mol Neurosci (2016) 0.79
Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation. J Neurosci (2016) 0.79
Upregulation of Parkin in endophilin mutant mice. J Neurosci (2014) 0.78
Leucine-rich repeat kinase-1 regulates osteoclast function by modulating RAC1/Cdc42 Small GTPase phosphorylation and activation. Am J Physiol Endocrinol Metab (2016) 0.75
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias. Mol Brain (2016) 0.75
The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2. Sci Rep (2016) 0.75
Role and mechanism of action of leucine-rich repeat kinase 1 in bone. Bone Res (2017) 0.75
Endogenous Leucine-Rich Repeat Kinase 2 Slows Synaptic Vesicle Recycling in Striatal Neurons. Front Synaptic Neurosci (2017) 0.75
G2385R and I2020T Mutations Increase LRRK2 GTPase Activity. Biomed Res Int (2016) 0.75
The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Sci Rep (2017) 0.75
Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. Sci Rep (2017) 0.75
The BigLEN-GPR171 Peptide Receptor System within the Basolateral Amygdala Regulates Anxiety-Like Behavior and Contextual Fear Conditioning. Neuropsychopharmacology (2017) 0.75
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc (2009) 32.64
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR (1996) 29.55
EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52
The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res (2010) 18.73
The Protein Data Bank. Acta Crystallogr D Biol Crystallogr (2002) 14.44
Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol Cell Proteomics (2005) 10.60
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res (1993) 9.81
Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol (1983) 7.55
Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal Biochem (1993) 6.78
Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field. Proteins (2002) 6.21
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
The Protein Data Bank and the challenge of structural genomics. Nat Struct Biol (2000) 4.21
Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci (1996) 4.21
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
WD40 proteins propel cellular networks. Trends Biochem Sci (2010) 3.17
Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci (2003) 3.15
Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta (2003) 2.62
LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci (2011) 2.52
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
Identification of the versatile scaffold protein RACK1 on the eukaryotic ribosome by cryo-EM. Nat Struct Mol Biol (2004) 2.27
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Exo-endocytotic recycling of synaptic vesicles in developing processes of cultured hippocampal neurons. J Cell Biol (1992) 2.09
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
Cytosolic Sec13p complex is required for vesicle formation from the endoplasmic reticulum in vitro. J Cell Biol (1993) 2.00
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem (2009) 1.71
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
It's the machine that matters: Predicting gene function and phenotype from protein networks. J Proteomics (2010) 1.57
Structure of a signal transduction regulator, RACK1, from Arabidopsis thaliana. Protein Sci (2008) 1.52
LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord (2006) 1.47
Structural and functional analysis of essential pre-mRNA splicing factor Prp19p. Mol Cell Biol (2005) 1.42
The WD40 domain is required for LRRK2 neurotoxicity. PLoS One (2009) 1.32
Diversity of WD-repeat proteins. Subcell Biochem (2008) 1.28
The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet (2006) 1.27
Tandem affinity purification of protein complexes from mammalian cells by the Strep/FLAG (SF)-TAP tag. Methods Mol Biol (2009) 1.18
A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics (2010) 1.15
A method for WD40 repeat detection and secondary structure prediction. PLoS One (2013) 1.14
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J (2012) 1.11
The role of Saccharomyces cerevisiae Cdc40p in DNA replication and mitotic spindle formation and/or maintenance. Mol Gen Genet (1995) 1.11
Genetics of Parkinson's disease: LRRK2 on the rise. Brain (2005) 1.09
LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet (2011) 1.08
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci (2014) 1.08
Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord (2010) 1.01
Proteomic analysis of activity-dependent synaptic plasticity in hippocampal neurons. J Proteome Res (2007) 1.01
Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int J Biochem Cell Biol (2006) 0.96
LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi-center pooled analysis. Am J Med Genet B Neuropsychiatr Genet (2009) 0.94
Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur J Hum Genet (2006) 0.91
Tyrosine phosphorylation of synapsin I by Src regulates synaptic-vesicle trafficking. J Cell Sci (2010) 0.90
Neurite degeneration induced by heme deficiency mediated via inhibition of NMDA receptor-dependent extracellular signal-regulated kinase 1/2 activation. J Neurosci (2007) 0.90
Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore (2006) 0.88
RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem (2008) 0.87
Endosomal recycling regulation during cytokinesis. Commun Integr Biol (2009) 0.84
Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. Biochem Soc Trans (2012) 0.81
ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2? J Neurosci Methods (2013) 0.81
Parkinson's disease. Clin Evid (2005) 0.76